RxSight, Inc. to Present at the Wells Fargo Healthcare Conference
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Wells Fargo Healthcare Conference in Boston.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
RxSight (NASDAQ:RXST), an ophthalmic medical device company focused on post-cataract surgery vision customization, has announced its participation in the upcoming Wells Fargo Healthcare Conference in Boston. The company's management will deliver their presentation on September 4, 2025, at 10:15 AM ET. Investors can access both the live and archived versions of the presentation through the company's investor relations website at investors.rxsight.com.
Details
News Market Reaction – RXST
On Aug 15, the first trading day after this news, RXST closed 2.55% above the previous close.
Data tracked by StockTitan Argus for the Aug 15 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALISO VIEJO, Calif., Aug. 14, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming Wells Fargo Healthcare Conference in Boston.
RxSight’s management is scheduled to present on Thursday, September 4, 2025, at 7:15 a.m. Pacific Time / 10:15 a.m. Eastern Time. A live and archived webcast of the presentation will be available at: https://investors.rxsight.com/.
About RxSight, Inc.
RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL®/LAL+®), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.
Company Contact:
Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com
Investor Relations Contact:
Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.